Brett Rawlins
Family · Kaysville, UTNPI 1295983831
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,838 of the $149,184 with a category attached, or 70.3%. 44 manufacturers reported payments, led by Novo Nordisk at 56.0% of the total. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 972 payments — averaging $153.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$83K
- Abbott$34K
- Corcept Therapeutics$17K
- Lilly USA, LLC$5K
- Medtronic$2K
- Insulet Corporation$2K
- plus $6K from 38 others
What the payments were for
- Consulting fees$4,4033%
- Speaking & faculty fees$104,83870%
- Travel & lodging$23,02415%
- Food & beverage$16,83611%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$44,637
- Ozempic$30,592
- FREESTYLE LIBRE 3$22,218
- Korlym$16,362
- FreeStyle Libre$6,829
- LYUMJEV$3,900
- Omnipod$2,012
- MINIMED 780G$1,635
- FreeStyle Libre 2$729
- FreeStyle Libre Pro$135
- TZIELD$127
- Wegovy$122
- Qutenza$120
- DEXCOM G6 TRANSMITTER$118
How this compares
$149,184 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 204 | $286,084 |
| MounjaroTirzepatide | 172 | $219,790 |
| Humalog Kwikpen U-200Insulin Lispro | 54 | $169,103 |
| JardianceEmpagliflozin | 88 | $99,175 |
| TrulicityDulaglutide | 77 | $98,535 |
| Humulin R U-500Insulin Regular, Human | 48 | $83,497 |
| RybelsusSemaglutide | 44 | $70,060 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $58,110 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $52,011 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $44,767 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $21,361 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $19,230 |
| FarxigaDapagliflozin Propanediol | 24 | $18,975 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 16 | $18,254 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $16,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $83,479 | $365,477263 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $4,766 | $328,491274 claims |
| Boehringer IngelheimJardiance, Synjardy | $291 | $120,536102 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $736 | $19,23022 claims |
| AstraZenecaFarxiga | $93 | $18,97524 claims |
| AbbVieSynthroid | $184 | $1,12015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.
Other family in Kaysville
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$395K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Shelby MillerSandy$140K
- Kindra HuntProvo$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.